MorphoSys (MOR) Given a €107.00 Price Target by Commerzbank Analysts

Commerzbank set a €107.00 ($124.42) target price on MorphoSys (ETR:MOR) in a research report sent to investors on Tuesday. The firm currently has a neutral rating on the stock.

MOR has been the topic of several other reports. Independent Research set a €120.00 ($139.53) target price on MorphoSys and gave the stock a neutral rating in a research note on Tuesday, August 7th. JPMorgan Chase & Co. reiterated a buy rating and set a price target on shares of MorphoSys in a research note on Thursday, November 1st. Royal Bank of Canada set a €65.00 ($75.58) price target on MorphoSys and gave the company a sell rating in a research note on Monday, October 15th. Oddo Bhf set a €110.00 ($127.91) price target on MorphoSys and gave the company a buy rating in a research note on Thursday, October 11th. Finally, Deutsche Bank set a €120.00 ($139.53) price target on MorphoSys and gave the company a neutral rating in a research note on Monday, July 30th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company. MorphoSys presently has a consensus rating of Hold and an average target price of €96.40 ($112.09).

Shares of MOR stock opened at €103.90 ($120.81) on Tuesday. MorphoSys has a 1-year low of €49.63 ($57.71) and a 1-year high of €88.10 ($102.44).

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Recommended Story: Penny Stocks, Risk and Reward Factors

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply